Bismuth(III) ion (Bi3+)

Bismuth ions (Bi3+) are the active pharmacological species released from bismuth-containing compounds used primarily in gastroenterology (StatPearls, 2023). They possess a unique multi-targeted mechanism of action, making them highly effective against Helicobacter pylori, where they inhibit bacterial enzymes like urease and disrupt cell membrane integrity (PubMed, 2000). Beyond their antimicrobial properties, bismuth ions provide significant cytoprotective effects to the gastric mucosa by promoting the synthesis of protective factors like prostaglandins and forming a physical barrier over lesions (DrugBank, 2024). Clinically, they are a cornerstone of quadruple therapy for peptic ulcers and are widely used for the symptomatic relief of diarrhea and dyspepsia (NIH, 2023). While bismuth is generally well-tolerated, its use requires monitoring to prevent rare but serious systemic toxicity, such as encephalopathy, particularly with prolonged or high-dose administration (Wikipedia, 2024).

Other names

Bismuth cationBi(III)Bi+3Bismuth(3+)

Bismuth ions exert antimicrobial effects by binding to bacterial thiols and inhibiting key enzymes such as urease, which is critical for H. pylori survival (PubMed, 2000). They also disrupt bacterial cell walls and interfere with ATP synthesis. In the gastric environment, they provide cytoprotection by stimulating prostaglandin and mucus secretion and forming a protective protein-bismuth complex over ulcer craters (StatPearls, 2023).